The Wall Street lender is targeting senior-level additions in Japan, particularly in sectors such as technology, media and telecommunications, while also preparing for expansion in China pending final regulatory approval for its wholly owned securities business, Kaustubh Kulkarni, Citi’s Asia head of investment banking, said on Monday.

Despite geopolitical tensions, including disruptions linked to the Iran conflict, Citi is pressing ahead with regional growth plans as deal activity across Asia remains relatively resilient, driven by corporate restructuring, governance reforms and strategic acquisitions.

“Japanese companies are becoming a lot more creative and open for strategic conversations,” Kulkarni said, pointing to governance-driven changes in corporate structures and rising shareholder activism as key drivers of stronger client engagement.

He said the bank wants to close coverage gaps in Japan by hiring senior bankers who can provide the level of client access and leadership that local companies value, while improving coordination between domestic and international teams to win more cross-border M&A mandates and sponsor-related transactions.

Some emerging markets such as Indonesia and the Philippines, which are more sensitive to energy shocks, have seen slower initial public offering and capital markets activity, Kulkarni said. By contrast, deal momentum in Japan, South Korea and Taiwan has remained stronger because those markets are less directly exposed to such volatility.

Citi’s global investment banking fees rose 12% year-on-year in the first quarter, reflecting stronger advisory and capital markets activity across several regions.In China, the bank is awaiting final approval from regulators to operate its own securities unit, which would house its onshore investment banking business.

Kulkarni said the firm had already entered hiring mode for China, with a focus on bankers capable of covering “new-age” and high-growth companies, though he declined to provide details on specific appointments.

Hong Kong’s offshore equity capital markets have also shown a strong recovery, with more than HK$140 billion ($18 billion) raised through initial public offerings by late April, marking the strongest start to a year since 2021 and representing an increase of more than 400% from the same period a year earlier.

Citi is also considering a third senior hire in Australia to complete a broader regional buildout after appointing two senior bankers in healthcare and natural resources to strengthen leadership coverage in those sectors.

Kulkarni became Citi’s sole head of Asia investment banking after former co-head Jan Metzger left in March to join Standard Chartered.

The expansion signals Citi’s intention to reinforce its advisory franchise in Asia as competition intensifies among global banks for regional M&A and capital markets mandates, particularly in Japan and Greater China where corporate restructuring and cross-border transactions .

India’s largest drugmaker by market value said it would pay $14 per share for Organon, representing a premium of more than 24% to Organon’s April 24 closing price, as it accelerates its strategy to deepen exposure to higher-margin specialty therapies including dermatology, oncology and obesity treatments.

The acquisition also strengthens Sun Pharma’s presence in women’s health and gives it entry into biosimilars, while broadening its reach into markets such as China, Brazil and other emerging economies where its footprint has been comparatively limited.

Sun Pharma shares closed 7% higher on Monday, adding 271.36 billion rupees ($2.88 billion) in market value, after rising as much as 9% earlier in the session. Organon shares rose 16% in premarket U.S. trading to $14.06.The deal includes Organon’s net debt of about $8.6 billion as of Dec. 31, 2025.

Sun said it would finance the transaction through a combination of existing cash reserves and committed bank financing.As of the same date, Sun Pharma’s debt stood at roughly $198.4 million, while annual profit was about $1.16 billion, giving it relatively strong balance sheet flexibility compared with the scale of the acquisition.

Analysts said the transaction would materially increase Sun’s earnings capacity and strengthen its long-term strategic positioning.Nuvama Institutional Equities analyst Shrikant Akolkar said the acquisition would effectively double Sun’s revenue and EBITDA by adding approximately $6.2 billion in sales with EBITDA margins of around 30%.

He said the transaction could be 30% to 40% earnings-per-share accretive by fiscal year 2028.“Funding is coming from a strong balance sheet, and debt concerns should ease by the third year,” Akolkar said, adding that the deal positions Sun to become a more dominant global pharmaceutical player by the end of the decade.

Organon’s portfolio includes more than 70 women’s health and general medicine products sold across around 140 countries, offering Sun a steady cash-generating business alongside its specialty drug pipeline.

The acquisition comes as Indian drugmakers with significant U.S. exposure face pressure from shifting U.S. tariff policies and pricing challenges in the generics market, prompting companies to seek stronger margins through branded specialty medicines and broader geographic diversification.

While analysts view the deal as strongly positive for earnings, some noted it may not dramatically alter Sun’s competitive standing in the U.S. market because Organon’s American business remains relatively modest.

Still, the transaction represents a major strategic step for Sun Pharma as it seeks to reduce dependence on traditional generic drug sales and strengthen its position as a global branded and specialty pharmaceuticals player.

Despite a wave of senior banker exits, the Wall Street powerhouse remains firmly at the top of the global M&A charts, signaling resilience, strategic renewal, and a stronger path ahead for 2026.

Goldman Sachs, one of the world’s leading investment banks, is entering a new phase of strategic transformation and leadership renewal. While over a dozen senior investment bankers have left the firm in 2025 — a higher-than-usual turnover — insiders and analysts say the departures come as part of a natural realignment in response to shifting market conditions, leadership restructuring, and evolving business strategies.

Despite the movement, Goldman Sachs continues to dominate global mergers and acquisitions (M&A), topping Wall Street’s league tables and maintaining one of its strongest financial performances since 2021. The firm’s investment banking net revenue for the first nine months of the year surged to its highest level in four years, proving that Goldman’s core business remains robust even amid industry-wide slowdowns.

Leadership Renewal and Organizational Evolution

In 2025, Goldman Sachs introduced significant leadership changes across its divisions, appointing new co-heads and six additional members to its management committee. These moves reflect the bank’s ongoing commitment to agility, accountability, and innovation in a rapidly changing financial landscape.

Additionally, the firm created a new financing division to strengthen its integrated services and enhance client offerings in an increasingly competitive environment. This structural evolution has been well-received by analysts, who view the reshuffle as a forward-looking strategy that positions Goldman for sustained growth as global dealmaking activity recovers.

“The expectation for a bigger M&A environment has been in place for some time,” said Macrae Sykes, portfolio manager at Gabelli Funds. “Goldman Sachs is well-prepared to take advantage of the tailwinds given their franchise strength and broad-based banking capabilities. Headcount may fluctuate, but not the firm’s productivity or culture.”

Continued Market Leadership

Even as some senior bankers transition to other institutions like JPMorgan Chase, Wells Fargo, Citigroup, and boutiques such as Evercore, Goldman remains a clear leader in M&A advisory.

The firm advised Electronic Arts on its $55 billion sale to a consortium of private equity firms and Saudi Arabia’s Public Investment Fund, and Holcim on the $26 billion spinoff of its North American business, Amrize — both among the largest global deals of the year.

Industry-wide, the scale of megadeals has jumped 40% year over year, reaching $1.26 trillion in global M&A activity during the third quarter, according to Dealogic data. Even with a 16% decline in deal volume, Goldman’s ability to lead on high-value transactions demonstrates its unmatched expertise and market reach.

A Culture of Resilience and Inclusion

Goldman Sachs’ internal culture remains a cornerstone of its success. The bank continues to prioritize talent development and diversity, with 95 new partners appointed in 2024 — including 26 women, marking one of the most inclusive partner classes in its history.

The firm’s adaptability and focus on long-term growth have also been reflected in its share performance. Goldman’s stock has risen nearly 38% in 2025, far outpacing the S&P 500 Financials Index, which grew 11%. This surge underscores strong investor confidence in Goldman’s strategy and ability to navigate evolving economic conditions.

A company spokesperson reaffirmed the firm’s outlook, saying, “Goldman Sachs succeeds because of our exceptional teams and the strength of our franchise. We continue to run our firm in service of our clients and shareholders — that’s where our focus remains.”

Looking Ahead: A Stronger 2026

The firm plans to announce a new class of partners in 2026, continuing its tradition of rewarding excellence and leadership. As the M&A environment improves and capital markets regain momentum, analysts predict that Goldman’s streamlined operations, renewed leadership, and robust client pipeline will drive another year of strong performance.

In a time when many institutions are contracting, Goldman Sachs is realigning, refocusing, and reemerging stronger. Its proactive restructuring, sustained deal leadership, and solid financial trajectory paint a picture of a company not in decline — but in strategic ascent.